An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine c...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005321/full |
| _version_ | 1811313825518977024 |
|---|---|
| author | Li Chen Li Chen Haiwei Zhang Moxuan Li Moxuan Li Bihao Wu Bihao Wu Zhe Zhang Rui Gong Rui Gong Rui Gong |
| author_facet | Li Chen Li Chen Haiwei Zhang Moxuan Li Moxuan Li Bihao Wu Bihao Wu Zhe Zhang Rui Gong Rui Gong Rui Gong |
| author_sort | Li Chen |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine consisting of the SARS-CoV-2 receptor binding domain (RBD) fused to the antibody Fc fragment (RBD-Fc). RBD-Fc could induce strong humoral immune responses via intranasal vaccination. Notably, this immunogen could efficiently induce IgG and IgA and establish mucosal immunity in the respiratory tract. The induced antibodies could efficiently neutralize wild-type SARS-CoV-2 and currently identified SARS-CoV-2 VOCs, including the Omicron variant. In a mouse model, intranasal immunization could provide complete protection against a lethal SARS-CoV-2 challenge. Unfortunately, the limitation of our study is the small number of animals used in the immune response analysis. Our results suggest that recombinant RBD-Fc delivered via intranasal vaccination has considerable potential as a mucosal vaccine that may reduce the risk of SARS-CoV-2 infection. |
| first_indexed | 2024-04-13T11:00:30Z |
| format | Article |
| id | doaj.art-e5f4ffe85a5b47e9b26cdfb5eed05fe8 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T11:00:30Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e5f4ffe85a5b47e9b26cdfb5eed05fe82022-12-22T02:49:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-11-011310.3389/fimmu.2022.10053211005321An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune responseLi Chen0Li Chen1Haiwei Zhang2Moxuan Li3Moxuan Li4Bihao Wu5Bihao Wu6Zhe Zhang7Rui Gong8Rui Gong9Rui Gong10CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, ChinaUniversity of Chinese Academy of Sciences, Beijing, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, ChinaUniversity of Chinese Academy of Sciences, Beijing, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, ChinaUniversity of Chinese Academy of Sciences, Beijing, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, ChinaUniversity of Chinese Academy of Sciences, Beijing, ChinaHubei Jiangxia Laboratory, Wuhan, Hubei, ChinaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine consisting of the SARS-CoV-2 receptor binding domain (RBD) fused to the antibody Fc fragment (RBD-Fc). RBD-Fc could induce strong humoral immune responses via intranasal vaccination. Notably, this immunogen could efficiently induce IgG and IgA and establish mucosal immunity in the respiratory tract. The induced antibodies could efficiently neutralize wild-type SARS-CoV-2 and currently identified SARS-CoV-2 VOCs, including the Omicron variant. In a mouse model, intranasal immunization could provide complete protection against a lethal SARS-CoV-2 challenge. Unfortunately, the limitation of our study is the small number of animals used in the immune response analysis. Our results suggest that recombinant RBD-Fc delivered via intranasal vaccination has considerable potential as a mucosal vaccine that may reduce the risk of SARS-CoV-2 infection.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005321/fullSARS-CoV-2intranasal vaccineRBD-Fcmucosal immunitymucosal vaccine |
| spellingShingle | Li Chen Li Chen Haiwei Zhang Moxuan Li Moxuan Li Bihao Wu Bihao Wu Zhe Zhang Rui Gong Rui Gong Rui Gong An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response Frontiers in Immunology SARS-CoV-2 intranasal vaccine RBD-Fc mucosal immunity mucosal vaccine |
| title | An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response |
| title_full | An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response |
| title_fullStr | An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response |
| title_full_unstemmed | An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response |
| title_short | An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response |
| title_sort | intranasal vaccine targeting the receptor binding domain of sars cov 2 elicits a protective immune response |
| topic | SARS-CoV-2 intranasal vaccine RBD-Fc mucosal immunity mucosal vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005321/full |
| work_keys_str_mv | AT lichen anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT lichen anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT haiweizhang anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT moxuanli anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT moxuanli anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT bihaowu anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT bihaowu anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT zhezhang anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT ruigong anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT ruigong anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT ruigong anintranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT lichen intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT lichen intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT haiweizhang intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT moxuanli intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT moxuanli intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT bihaowu intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT bihaowu intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT zhezhang intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT ruigong intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT ruigong intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse AT ruigong intranasalvaccinetargetingthereceptorbindingdomainofsarscov2elicitsaprotectiveimmuneresponse |